# SYNC-T Therapy SV-102

Source: https://onco.cc/drugs/sv-102/  
OnCo record `sv-102` (Device or software). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

SYNC-T Therapy SV-102 is an experimental intratumoral multi-agent immunotherapy given with partial cryolysis from Syncromune, in phase 2 trials for metastatic castration-resistant prostate cancer.

## Summary

SYNC-T Therapy SV-102 (SV-102, SYNC-T) is an intratumoral multi-agent immunotherapy given with partial cryolysis (drug-device combination) from Syncromune, with Williams Cancer Foundation as sponsor of the phase 1 trial. A small part of one tumour is frozen and thawed to release tumour antigens, then SV-102 - four immune agents: abazistobart (anti-PD-1), futermestotug (anti-CTLA-4), ciltistotug (CD40 agonist) and sitmutolimod (TLR9 agonist) - is infused into the same tumour. Its furthest stage is phase 2, for metastatic castration-resistant prostate cancer. ClinicalTrials.gov registers it in 2 studies linked below. Whether it works in people has not been established unless a trial below reports it.

## Fields

- Kind: Device or software
- Status: phase-2
- Last checked: 2026-11-03
- Also known as: SV-102; SYNC-T
- Tags: pipeline; ctgov-ingest
- Code: SV-102
- Modality: Intratumoral multi-agent immunotherapy given with partial cryolysis (drug-device combination)
- Mechanism: A small part of one tumour is frozen and thawed to release tumour antigens, then SV-102 - four immune agents: abazistobart (anti-PD-1), futermestotug (anti-CTLA-4), ciltistotug (CD40 agonist) and sitmutolimod (TLR9 agonist) - is infused into the same tumour.

## Sources

- Syncromune: syncromune.com: https://syncromune.com/2026/10/27/syncromune-reports-long-term-data-from-phase-1-study-in-metastatic-prostate-cancer-with-investigational-sync-t-therapy-sv-102/
- Syncromune: syncromune.com: https://syncromune.com/2026/10/27/syncromune-reports-long-term-data-from-phase-1-study-in-metastatic-prostate-cancer-with-investigational-sync-t-therapy-sv-102/
- ClinicalTrials.gov: trials of SV-102: https://clinicaltrials.gov/search?intr=SV-102

## Connected records

- cancers: [Metastatic castration-resistant prostate cancer](https://onco.cc/cancers/prostate-mcrpc/)
- targets: [CD40](https://onco.cc/targets/cd40/), [CTLA-4](https://onco.cc/targets/ctla4/), [PD-1](https://onco.cc/targets/pd1/)
- companies: [Syncromune](https://onco.cc/companies/syncromune/)
- trials: [A Study of SYNC-T Therapy SV-102 in Participants With Metastatic Castration-Resistant Prostate Cancer](https://onco.cc/trials/nct06533644/), [Phase 1 Trial of SYNC-T - Immunotherapy for Advanced/Metastatic Castration-Resistant Prostate Cancer](https://onco.cc/trials/nct05544227/)

---
JSON: https://onco.cc/api/v1/entities/sv-102.json